Evidence map›Paper›PMID 34063339›Full record

ReviewNutrients2021

Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.

Matteo Iervolino, Elisa Lepore, Gianpiero Forte, Antonio Simone Laganà, Giovanni Buzzaccarini, Vittorio Unfer

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 6 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 6 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Review
  14. Long Noncoding RNA NONHSAT233728.1 Promotes ROS Accumulation and Granulosa Cell Apoptosis by Regulating the MAPK/ERK1/2 Signaling Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  15. Polycystic Ovarian Syndrome: A Review of Multi-omics Analyses.Reproductive sciences (Thousand Oaks, Calif.) · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Matteo IervolinoR&D Department, Lo.Li. Pharma Srl, 00156 Rome, Italy.
Elisa LeporeR&D Department, Lo.Li. Pharma Srl, 00156 Rome, Italy.
Gianpiero ForteR&D Department, Lo.Li. Pharma Srl, 00156 Rome, Italy.
Antonio Simone LaganàDepartment of Obstetrics and Gynecology, "Filippo Del Ponte" Hospital, University of Insubria, 2100 Varese, Italy.ORCID 0000-0003-1543-2802
Giovanni BuzzaccariniUnit of Gynecology and Obstetrics, Department of Women and Children's Health, University of Padua, 35128 Padua, Italy.ORCID 0000-0002-9466-0178
Vittorio UnferThe Experts Group on Inositol in Basic and Clinical Research (EGOI), 00156 Rome, Italy.
European Gravitational Observatory · ITUniversity of Insubria · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is a heterogenous disorder characterized by chronic ovulation dysfunction and hyperandrogenism. It is considered the most common endocrinological disorder, affecting up to 25% of women of reproductive age, and associated with long-term metabolic abnormalities predisposing to cardiovascular risk, such as insulin resistance (IR), dyslipidemia, endothelial dysfunction, and systemic inflammation. PCOS is also characterized by elevated serum levels of luteinizing hormone (LH), causing a condition of hyperandrogenism and a consequent altered ratio between LH and the follicle stimulating hormone (FSH). Over the years, several different approaches have been proposed to alleviate PCOS symptoms. Supplementation with natural molecules such as inositols, resveratrol, flavonoids and flavones, vitamin C, vitamin E and vitamin D, and omega-3 fatty acids may contribute to overcoming PCOS pathological features, including the presence of immature oocyte, IR, hyperandrogenism, oxidative stress and inflammation. This review provides a comprehensive overview of the current knowledge about the efficacy of natural molecule supplementation in the management of PCOS.

Indexed as

Ascorbic AcidDietary SupplementsDyslipidemiasFatty Acids, Omega-3FemaleFlavanonesFlavonoidsFollicle Stimulating HormoneHumansHyperandrogenismInositolInsulin ResistanceLuteinizing HormoneOvulationPolycystic Ovary SyndromeResveratrolAscorbic AcidFatty Acids, Omega-3FlavanonesFlavonoidsFollicle Stimulating HormoneInositolLuteinizing HormoneResveratrolVitamin DVitamin EVitaminsD-chiro-inositolmyo-inositolomega-3 fatty acidspolycystic ovary syndromeresveratrolvitamin Cvitamin Dvitamin E

Identifiers

PMID34063339
PMCPMC8156462
OpenAlexW3160583309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.